Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
Katrina L PaumierParkinson Study Group Genetics Epidemiology Working Group

Abstract

This study examined whether antidepressants delay the need for dopaminergic therapy or change the degree of motor impairment and disability in a population of early Parkinson's disease (PD) patients. Preclinical studies have indicated that antidepressants modulate signaling pathways involved in cell survival and plasticity, suggesting they may serve to both treat PD-associated depression and slow disease progression. A patient-level meta-analysis included 2064 patients from the treatment and placebo arms of the following trials: FS1, FS-TOO, ELLDOPA, QE2, TEMPO, and PRECEPT. Depression severity was determined at baseline, and antidepressant use was reported in a medication log each visit. Kaplan-Meier curves and time-dependent Cox proportional hazards models determined associations between depression severity and antidepressant use with the primary outcome, time to initiation of dopaminergic therapy. ANCOVAs determined associations with the secondary outcome, degree of motor impairment and disability, reported as annualized change in UPDRS scores from baseline to final visit. When controlling for baseline depression, the initiation of dopaminergic therapy was delayed for subjects taking tricyclic antidepressants compared with t...Continue Reading

References

Mar 1, 1992·Archives of Neurology·G DooneiefR Mayeux
Jan 1, 1982·Journal of Psychiatric Research·J A YesavageV O Leirer
Dec 1, 1996·Neurology·W H Poewe, G K Wenning
Sep 28, 1998·Annals of Neurology·W H Poewe, G K Wenning
Oct 11, 2002·Archives of Neurology·Clifford W ShultsUNKNOWN Parkinson Study Group
Dec 21, 2002·Archives of Neurology·UNKNOWN Parkinson Study Group
Jun 20, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·UNKNOWN Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease
Aug 2, 2003·Biological Psychiatry·William M McDonaldMahlon R DeLong
Jun 1, 1961·Archives of General Psychiatry·A T BECKJ ERBAUGH
Apr 28, 2005·Expert Review of Neurotherapeutics·Connie Marras, Antony E Lang
Sep 10, 2005·Clinical Neurology and Neurosurgery·Spiridon PapapetropoulosNicoletta P Lekka
Jun 27, 2006·Journal of the Neurological Sciences·Anette Schrag
Jan 4, 2007·Neurology·UNKNOWN NINDS NET-PD Investigators
Aug 23, 2007·Journal of Geriatric Psychiatry and Neurology·Peijun ChenAlan M Mellow
May 1, 2008·The International Journal of Neuroscience·Pasquale G FrisinaNancy S Foldi
Oct 17, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Zaorui ZhaoJames M O'Donnell
Oct 28, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Madaline B HarrisonG Frederick Wooten
Feb 10, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Anette SchragRichard Dodel
May 5, 2009·Movement Disorders : Official Journal of the Movement Disorder Society·Matthew MenzaAllison Dicke
Jun 23, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Young C ChungByung K Jin
Apr 22, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jürgen ZschockeTheo Rein

❮ Previous
Next ❯

Citations

Jul 3, 2013·Experimental Brain Research·Philippe Huot, Susan H Fox
Oct 1, 2013·European Archives of Psychiatry and Clinical Neuroscience·Julian Hellmann-RegenChristian Otte
Nov 6, 2013·Current Neurology and Neuroscience Reports·Laura Marsh
Sep 21, 2012·Current Opinion in Psychiatry·Sergio E StarksteinBradleigh D Hayhow
Mar 27, 2015·Parkinson's Disease·Philippe HuotJonathan M Brotchie
Oct 1, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Katrina L PaumierTimothy J Collier
Jul 25, 2015·Movement Disorders : Official Journal of the Movement Disorder Society·Lorraine V KaliaAnthony E Lang
Apr 13, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Anthony E Lang, Alberto J Espay
Feb 23, 2020·Frontiers in Neurology·Min WangChanglian Tan
Dec 18, 2013·CNS Neuroscience & Therapeutics·Gonglin HouTi-Fei Yuan
Mar 3, 2021·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Gregory M Pontone, Kelly A Mills

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.